168 related articles for article (PubMed ID: 14613025)
1. Dysregulation of cellular signaling by HER2/neu in breast cancer.
Zhou BP; Hung MC
Semin Oncol; 2003 Oct; 30(5 Suppl 16):38-48. PubMed ID: 14613025
[TBL] [Abstract][Full Text] [Related]
2. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
3. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
Bhat-Nakshatri P; Sweeney CJ; Nakshatri H
Oncogene; 2002 Mar; 21(13):2066-78. PubMed ID: 11960379
[TBL] [Abstract][Full Text] [Related]
4. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas.
Schroeder JA; Adriance MC; McConnell EJ; Thompson MC; Pockaj B; Gendler SJ
J Biol Chem; 2002 Jun; 277(25):22692-8. PubMed ID: 11950845
[TBL] [Abstract][Full Text] [Related]
5. HER2 overexpression and cancer targeting.
Wang SC; Hung MC
Semin Oncol; 2001 Oct; 28(5 Suppl 16):115-24. PubMed ID: 11706403
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Piechocki MP; Yoo GH; Dibbley SK; Lonardo F
Cancer Res; 2007 Jul; 67(14):6825-43. PubMed ID: 17638894
[TBL] [Abstract][Full Text] [Related]
7. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.
Tari AM; Lim SJ; Hung MC; Esteva FJ; Lopez-Berestein G
Oncogene; 2002 Aug; 21(34):5224-32. PubMed ID: 12149644
[TBL] [Abstract][Full Text] [Related]
8. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
12. Distinct regulatory effect of the p34SEI-1 oncoprotein on cancer metastasis in HER2/neu-positive and -negative cells.
Jung S; Ohk J; Jeong D; Li C; Lee S; Duan J; Kim C; Lim JS; Yang Y; Kim KI; Lee MS
Int J Oncol; 2014 Jul; 45(1):189-96. PubMed ID: 24789658
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation.
Galang CK; García-Ramírez J; Solski PA; Westwick JK; Der CJ; Neznanov NN; Oshima RG; Hauser CA
J Biol Chem; 1996 Apr; 271(14):7992-8. PubMed ID: 8626480
[TBL] [Abstract][Full Text] [Related]
14. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
15. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Laughner E; Taghavi P; Chiles K; Mahon PC; Semenza GL
Mol Cell Biol; 2001 Jun; 21(12):3995-4004. PubMed ID: 11359907
[TBL] [Abstract][Full Text] [Related]
16. Novel targets of Akt, p21(Cipl/WAF1), and MDM2.
Zhou BP; Hung MC
Semin Oncol; 2002 Jun; 29(3 Suppl 11):62-70. PubMed ID: 12138399
[TBL] [Abstract][Full Text] [Related]
17. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
18. Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
Baumann J; Wong J; Sun Y; Conklin DS
BMC Cancer; 2016 Jul; 16():551. PubMed ID: 27464732
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells.
Simeone AM; Li YJ; Broemeling LD; Johnson MM; Tuna M; Tari AM
Cancer Res; 2004 Feb; 64(4):1224-8. PubMed ID: 14973114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
